Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.5952W HIGH $8.31
Volume
8.44 K
Value Traded
39.56 K
Short % Float
1.29%
Days to Cover
9.4
-1.03%Week
-1.43%1 Month
-16.49%3 Month
-18.34%6 Month
-39.17%5 Year
+15.09%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
66.95 M
EPS (TTM)
-0.08
P/E Ratio
-
Ent. Value
62.59 M
Total Shares
13.92 M
Float Shares
6.04 M
Insiders
56.62%
Institutions
18.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CSBR Catalyst Timeline
Dated clinical, regulatory and corporate events for Champions Oncology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Champions Oncology, Inc.
145Total events
0Upcoming
12Tier-1 (high impact)
2009 to 2026Coverage
Event history 50
▲Quarterly UpdateCorporate
Company reaffirms full-year revenue growth and positive adjusted EBITDA guidance
▲Management ChangeCorporate
Hired Matt Newman as EVP and General Manager for data licensing platform
▲Quarterly UpdateCorporate
Record quarterly revenue of $17.0M and net income of $4.5M for Q3 FY2025
▲Quarterly UpdateCorporate
Champions Oncology reports Q2 FY2025 revenue of $13.5M and adjusted EBITDA of $1.1M
▲Quarterly UpdateCorporate
Champions Oncology reports Q1 fiscal 2025 revenue of $14.1 million and adjusted EBITDA of $2.0 million
●Quarterly UpdateCorporate
Champions Oncology reports Q4 FY2024 revenue of $14.0M and annual revenue of $50.2M
◆Partnership / LicenseCorporate
Potential licensing deal for Corellia AI's two lead targets in coming quarters
▲Other Regulator MilestoneEx-US Regulatory
College of American Pathologists (CAP) accreditation awarded to US-based laboratory
▲Other Regulator MilestoneEx-US Regulatory
European lab received ISO accreditation and ATS certification
●Quarterly UpdateCorporate
Champions Oncology reports Q4 FY2023 revenue of $13.1M and annual revenue of $53.9M
●Preclinical PoCPreclinical
Commenced in-vivo efficacy testing for therapeutic hits on lead programs
●Timing GuidancePresentation
Discovery targets expected to advance to preclinical phase testing in calendar 2023
▲Partnership / LicenseCorporate
Series of antibody hits established in Alloy Therapeutics partnership
▲Partnership / LicenseCorporate
Signed co-development discovery partnerships with Fannin Innovation Studio and Gigamune
▲Quarterly UpdateCorporate
Year-to-date net cash provided by operating activities of $1.4 million for first six months FY2022
Past FDA Catalysts and PDUFA Decisions
How CSBR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CSBR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ACKERMAN JOELDirector | Option | 69,794 1,126,333 held | $1.60 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CSBR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.7 % (16.7 %) | 10.56 M | 1.71 M |
CSBR Institutional Ownership Trends
CSBR Short Interest
Shares sold short, counted twice a month.
1.29%
Short % of Float
of tradable shares sold short
77.7K
Shares Sold Short
+9.4% vs prior count
9.4 High
Days to Cover
trading days of normal volume to buy every short share back
8.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CSBR ranks across every disease it competes in
Competitive Position is a premium feature
See how CSBR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCSBR News
CSBRChampions Oncology Reports Revenue of $15.2 Million
Champions Oncology, Inc. reported a revenue increase of 8.8% for Q1 fiscal 2027, reaching $15.2 million. The oncology services margin improved to 51%, and adjusted EBITDA rose to $671,000. Despite these positive financial metrics, the company still faced a net loss of $426,000, reflecting ongoing investments in growth initiatives.
Read more →CSBRChampions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
Champions Oncology, Inc. will announce its financial results for the quarter ending July 31, 2026, on September 10, 2026. The announcement will occur after market close, followed by a conference call at 4:30 PM EDT. The company specializes in oncology research models and offers comprehensive R&D solutions for biopharma organizations.
Read more →CSBRChampions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging
Champions Oncology has expanded its integrated radiopharmaceutical development platform by introducing in-house SPECT/CT imaging capabilities. This enhancement allows researchers to visualize and quantify radiopharmaceutical uptake in vivo, linking it to tumor biology and therapeutic response. The platform aims to create richer datasets that support predictive development in oncology.
Read more →CSBRChampions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
Champions Oncology will present new data at the AACR 2026 Annual Meeting, showcasing eight studies that focus on oncology drug development. The research covers various cancer types and emphasizes the importance of understanding therapeutic responses and resistance. The company aims to help biopharma partners make informed decisions earlier in the development process. CEO Rob Brainin highlights the significance of combining patient-derived models with molecular data.
Read more →CSBRChampions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Champions Oncology appointed Dr. Brian Alexander to its Board of Directors, enhancing its focus on data-driven oncology research. Dr. Alexander's extensive experience in oncology and data science will support the company's strategy to connect patient-derived tumor models with molecular datasets. This approach aims to improve drug discovery and development outcomes.
Read more →CSBR▲ +6.3%on this news
Champions Oncology Reports Revenue of $16.6 Million
Champions Oncology reported a record study service revenue of $16.6 million for Q3 FY2026, marking a 32% increase year-over-year. Despite a slight decline in total revenue compared to the previous year, the company achieved its third consecutive quarter of positive adjusted EBITDA. CEO Robert Brainin expressed confidence in ongoing growth, particularly in their data business, while acknowledging fluctuations in quarterly results.
Read more →CSBR▲ +16.1%on this news
Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million
Champions Oncology, Inc. (Nasdaq CSBR) reported its financial results for the second quarter of fiscal 2026, highlighting an 11% increase in total revenue to $15 million compared to the previous year's quarter. Despite a net income of $237,000, which is lower than last year's equivalent, the company reported improved oncology services margins and maintained a positive adjusted EBITDA of $843,000. The management remains confident about sustainable revenue growth and is investing in its data platform to drive long-term value. The overall financial health shows both progress and challenges as expenses rise amidst ongoing investments.
Read more →CSBRChampions Oncology Advances Focus on Data and Discovery Partnerships with the Appointment of Dr Tammer Farid as General Manager of Champions’ Data Business
Champions Oncology appointed Dr. Tammer Farid as General Manager of its Data Business. He will enhance the company's data operations and product strategy, focusing on delivering multiomic datasets to biopharma partners. Dr. Farid aims to make the data more accessible and actionable for drug developers, leveraging Champions' extensive tumor model biobank.
Read more →CSBR▲ +21.5%on this news
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Champions Oncology, Inc. reported its financial results for Q1 of FY 2026, with total revenue at $14 million. Despite a slight decline in service revenue, the company experienced growth in its data license revenue. Newly appointed CEO Rob Brainin expressed optimism about sustainable growth and operational improvements. However, the financial report also highlighted a loss from operations and increased operating costs, indicating challenges alongside positive developments in revenue and market positioning.
Read more →CSBRChampions Oncology Reports Record Annual Revenue of $57 Million
Champions Oncology, Inc. reported a strong financial performance for the fiscal year 2025, with record annual revenue reaching $57 million, marking a 14% increase from the previous year. The company achieved net income of $4.6 million and adjusted EBITDA income of $7.1 million. However, the fourth quarter saw a decline in revenue by 12% and a loss from operations of $2 million. Despite these challenges, the company is optimistic about its growth prospects for fiscal 2026, driven by a solid pipeline and operational efficiencies.
Read more →CSBRChampions Oncology Announces Appointment of New CEO
Champions Oncology has appointed Rob Brainin as CEO, effective August 25, 2025. He succeeds Dr. Ronnie Morris, who will become Executive Chair. Brainin, with over 25 years in life sciences, aims to expand the company's data platform and enhance its therapeutic pipeline. Morris expressed confidence in Brainin's leadership for future growth.
Read more →CSBRChampions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Champions Oncology has launched its radiopharmaceutical services platform, enhancing its offerings in precision oncology. The company expanded its radioactive materials license to include ten key isotopes and completed the infrastructure for radiochemistry. This platform allows for integrated studies using patient-derived xenograft models, facilitating drug development with clinically relevant data.
Read more →CSBR▼ -7.5%on this news· ran to -19% by day 3
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
Champions Oncology has secured a license to use radioactive materials for preclinical studies. This approval enhances their ability to develop targeted radiotherapeutics using patient-derived xenograft models. CEO Ronnie Morris noted that this positions the company to better support biopharmaceutical partners in advancing next-generation radiopharmaceuticals.
Read more →CSBR▲ +10%on this news
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million
Champions Oncology, Inc. (Nasdaq: CSBR) reported compelling financial results for the third quarter of fiscal 2025, with total revenue increasing by 42% to $17.0 million and net income of $4.5 million. This quarter marks a transformative period for the company, notably due to its inaugural data licensing agreement valued at up to $8 million. Despite prevailing funding challenges in the biotech sector, Champions expressed confidence in maintaining strong performance driven by operational efficiencies and strategic cost alignments. Overall, the company has positioned itself for sustained long-term growth amidst a backdrop of improved financial metrics.
Read more →CSBR▲ +12.1%on this news
Non-GAAP Financial Information See the attached Reconciliation of GAAP net income (loss) to Non-GAAP net income (loss) for an explanation of the amounts excluded to arrive at Non-GAAP net income (loss) and related Non-GA
Champions Oncology, Inc. reported a 17% increase in total revenue, reaching $13.5 million for the second quarter of fiscal 2025. The company also achieved a positive adjusted EBITDA of $1.1 million and reiterated its optimistic outlook, projecting revenue growth of 10%-15% for the year. Despite these gains, research and development expenses saw a sharp decline, while costs related to oncology services increased slightly due to higher mouse costs. Overall, the results reflect operational efficiencies and a focus on enhancing revenue streams.
Read more →CSBRAbout Champions Oncology, Inc. Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R D solutions to biopharma organizations. With the largest and most annota
Champions Oncology, Inc. reported mixed financial results for the fiscal year ended April 30, 2024. While fourth quarter revenue rose by 7% to $14 million, the annual revenue saw a 7% decline. The company experienced an adjusted EBITDA loss of $3.9 million for the fiscal year, attributed to a challenging funding environment. However, cost-cutting measures began showing results in the fourth quarter, leading to an adjusted EBITDA income. The CEO expressed optimism about recovery signs in the market as the company prepares for fiscal 2025.
Read more →CSBRloss divided by the weighted average number of diluted shares outstanding. Champions' definition of Non-GAAP net loss and Non-GAAP diluted loss per share may differ from similarly named measures used by other companies a
Champions Oncology reported a third quarter revenue of $12.0 million, marking a 6% decline year-over-year. The gross margin also decreased to 35% as operational inefficiencies contributed to lower revenue. Despite these challenges, CEO Ronnie Morris highlighted confidence in future recovery and ongoing capital raising efforts for its subsidiary, Corellia, AI. The company's third-quarter loss from operations was $2.6 million, with strategic adjustments planned to improve performance moving forward.
Read more →CSBR▼ -6.5%on this news
See the attached Reconciliation of GAAP net loss to Non-GAAP net income (loss) for an explanation of the amounts excluded to arrive at Non-GAAP net income (loss) and related Non-GAAP income (loss) per share amounts for t
Champions Oncology, Inc. has reported its financial results for the second quarter of fiscal 2024, revealing a 19% decline in revenue to $11.6 million compared to the same period last year. The company revised its fiscal year revenue guidance to align with last year’s results amid a challenging economic environment impacting the biotech sector. Despite recent customer cancellations affecting revenue, management noted a recent resurgence in demand for its services and a healthy sales pipeline. Efforts are underway to raise capital for ongoing drug discovery initiatives and strategic developments under new leadership.
Read more →CSBRWebsite www.championsoncology.com Facebook https www.facebook.com championsoncology LinkedIn https www.linkedin.com company champions-oncology-inc- Twitter https twitter.com ChampionsOncol1 Instagram https www.instagram.
Champions Oncology, Inc. has appointed Brady Davis as its new President, aiming to advance strategic initiatives for accelerated growth. With over 25 years of international experience in the healthcare sector, Davis brings a strong background in medical instruments and data solutions. He will work alongside the executive team to enhance the company's market positioning and efficiency in oncology research. The appointment comes at a time of notable advancements in cancer research, aligning with Champions Oncology's commitment to innovative solutions.
Read more →About Champions Oncology, Inc.
Headquarters855 N. WOLFE STREET, BALTIMORE, MD, 21205
BIOPHARMAWATCH ELITE PLUS
Trade the next CSBR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime